The fog began to dissipate at least somewhat late last week regarding the reasons behind – and the potential immuno-oncology (IO) fallout from – Astrazeneca plc's phase III blowup with the MYSTIC trial in non-small-cell lung cancer (NSCLC), news of which came just as the pharma giant made public its $8.5 billion deal with Merck & Co. Inc. around the oral poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib).